Stocktoria
Doximity, Inc. DOCS
Doximity, Inc. (DOCS) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $644.9M at a 30.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.88 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-29 | B of A Securities | Underperform (down) |
| 2026-05-15 | Goldman Sachs | Neutral (main) |
| 2026-05-15 | Barclays | Equal-Weight (down) |
| 2026-05-14 | Leerink Partners | Outperform (main) |
| 2026-05-14 | Jefferies | Hold (down) |
| 2026-05-14 | Canaccord Genuity | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.702 |
| Retained earnings / assets | -0.045 |
| EBIT / assets | 0.191 |
| Equity / liabilities | 5.501 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DOCS | Doximity, Inc. | 5/9 | 11.52 | 19.5 | +13.1% |
| FORTY | FORMULA SYSTEMS (1985) LTD | 6/9 | 3.29 | 61.6 | +17.9% |
| PERI | Perion Network Ltd. | 3/9 | 5.93 | — | -11.7% |
| MLGO | MicroAlgo Inc. | 5/9 | — | — | -22.1% |
| TBRG | TruBridge, Inc. | 6/9 | 1.84 | 90.3 | +1.4% |
| RDNW | RideNow Group, Inc. | 6/9 | -3.1 | — | -10.5% |
| LZMH | LZ Technology Holdings Ltd | 2/9 | -4.93 | — | +43.2% |
About Doximity, Inc.
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
FAQ
Is DOCS financially healthy?
Doximity, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DOCS pay a dividend?
No, Doximity, Inc. does not currently pay a dividend.
How profitable is DOCS?
In FY2026, Doximity, Inc. had a net margin of 30.4% and a return on equity of 20.6%.
Is DOCS overvalued or undervalued?
Doximity, Inc. trades at about 25.5× trailing earnings — below its 10-year norm (10-year range 24.9×–69.3×, median 51.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for DOCS?
The average Wall-Street price target for Doximity, Inc. is $24.37, about 2.5% below the recent price, from 19 analysts (consensus: buy).
Is DOCS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Doximity, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 19.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.